Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
20.50
-1.70 (-7.66%)
At close: Nov 21, 2024, 4:00 PM
19.48
-1.02 (-4.98%)
After-hours: Nov 21, 2024, 5:18 PM EST

Oruka Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
10.616.285.855.54.773.98
Upgrade
Research & Development
26.031.014.7513.834.991.83
Upgrade
Operating Expenses
36.647.310.619.349.775.81
Upgrade
Operating Income
-36.64-7.3-10.6-19.34-9.77-5.81
Upgrade
Interest Expense / Income
0.50000.010.01
Upgrade
Other Expense / Income
-2.75-1.96-0.67-0.01-0.03-0.17
Upgrade
Pretax Income
-34.4-5.34-9.93-19.32-9.75-5.65
Upgrade
Income Tax
0000-0.01-0.17
Upgrade
Net Income
-34.4-5.34-9.93-19.32-9.74-5.48
Upgrade
Shares Outstanding (Basic)
1511100
Upgrade
Shares Outstanding (Diluted)
1511100
Upgrade
Shares Change
1150.26%0.04%3.64%195.18%256.50%71.72%
Upgrade
EPS (Basic)
-6.26-4.44-8.28-16.68-24.84-49.80
Upgrade
EPS (Diluted)
-6.26-4.44-8.28-16.68-24.84-49.80
Upgrade
Free Cash Flow
-40.25-5.01-10.91-18.81-7.74-4.81
Upgrade
Free Cash Flow Per Share
-2.68-4.17-9.09-16.23-19.73-43.64
Upgrade
Dividend Per Share
19.356-----
Upgrade
EBITDA
-33.8-5.23-9.81-19.23-9.65-5.55
Upgrade
Depreciation & Amortization
0.10.110.110.090.090.09
Upgrade
EBIT
-33.9-5.34-9.93-19.32-9.74-5.64
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).